Semi-Solid Dosage Contract Manufacturing Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 21.70 Bn

Forecast Year, 2035

USD 61.81 Bn

CAGR, 2026 - 2035

11.04%

Report Coverage

Global

What is the Semi-Solid Dosage Contract Manufacturing Market Size?

The global semi-solid dosage contract manufacturing market size accounted for USD 21.70 billion in 2025 and is predicted to increase from USD 24.13 billion in 2026 to approximately USD 61.81 billion by 2035, expanding at a CAGR of 11.04% from 2026 to 2035. The market is driven by rising topical treatment demand with modern drug delivery progress and cost savings from outsourcing with regulatory expertise and better patient drug usage.

Semi-Solid Dosage Contract Manufacturing Market Key Takeaways

• Asia Pacific dominated the market by generating more than 33% of the market share in 2025.
• North America is anticipated to grow at the fastest CAGR of 10.67% during the forecasted years.
• By type, the topical segment held the largest market share of 50% in 2025.
• By type, the transdermal segment is anticipated to show considerable growth over the forecast period.
• By product, the creams segment contributed the largest market share in 2025.
• By company size, the large-sized companies segment dominated the global market in 2025.
• By company size, the medium and small-sized companies segment is projected to show considerable growth in the forecast period.
• By end use, the pharmaceutical companies segment accounted for the largest market share in 2025.
• By end use, the cosmeceutical companies segment is anticipated to show considerable growth in the forecast period.

Market Overview

The semi-solid dosage contract manufacturing market functions as a sector that allows pharmaceutical companies to outsource their specialized production of creams, gels, ointments, and pastes through contract manufacturing organizations (CMOs). Pharmaceutical organizations increasingly depend on CMOs to cut operational expenses, gain new technologies, and simplify manufacturing procedures while continuing to operate without constructing their manufacturing plants.

The semi-solid dosage contract manufacturing market is expanding swiftly because pharmaceutical industries require these drugs to treat growing skin conditions and manage chronic pain, as well as improve drug delivery systems. The pharmaceutical industry shows increasing interest in outsourcing production activities; thus, the market expects steady growth. This market demonstrates growth because healthcare providers focus on improving patient outcomes and efficient treatments.

Artificial Intelligence (AI) Integration in the Semi-Solid Dosage Contract Manufacturing Market

The market benefits from artificial intelligence through better manufacturing processes, which drive efficiency and better product outcomes. Machine learning technologies and predictive analytics tools help optimize formulation developments, simplify production workflows, and detect potential manufacturing problems through early detection. AI functions as a monitoring system to enforce strict quality requirements that follow regulatory standards during production. The market grows due to AI integration that helps improve operational efficiency as well as decrease the time needed for product development.

Semi-Solid Dosage Contract Manufacturing Market Growth Factor

• Rising demand for topical treatments: Skin diseases prevalence increase, such as eczema, psoriasis, and acne, drives medical professionals towards using semi-solid formulations as topical treatments. The pharmaceutical markets expand due to patients indicating higher compliance and treatment success when they use creams and ointments as topical treatment methods.
• Regulatory compliance and expertise: Specialized contract manufacturing companies focus on meeting all regulatory requirements related to the production of semi-solid dosage forms. Pharmaceutical businesses receive faster market entry by using contract manufacturers that understand regulatory requirements, thereby generating new market opportunities for outsourced semi-solid dosage.

Market Scope

Market Dynamics

Drivers

Reduced Time-To-Market

CMOs maintain specialized expertise and production infrastructure that produces efficient management of pharmaceutical processes for rapid delivery times. Through a partnership with CMOs, pharmaceutical organizations escape manufacturing facility setup and maintenance responsibilities so they can dedicate their operations to innovation research. CMOs reduce production delays with scalable operations for delivering regulatory compliance and high product quality standards. Semi-solid dosage form CMOs have become essential for manufacturers because their quality-preserving rapid production speed drives extended market interest in contract manufacturing.

Restraint

Quality and Regulatory Compliance Challenges

With the development of semi-solid formulation products like creams, gels, and ointments, pharmaceutical companies experience major hurdles in meeting quality specifications and regulatory requirements. The production of these drugs requires complex procedures and testing, which ensures that all regulatory requirements, including the FDA and EMA's safety, efficacy, and quality standards.

Contract manufacturing organizations need to manage various regulatory standards across different regions because this increases operational complexities. The cost of regulatory compliance needs substantial investments in testing and documentation and regulatory validation exams to the extent that such expenses stress financial resources, especially for small-scale CMOs with minimal funding.

Opportunity

Advancements in drug deliver

Advanced drug delivery systems increasing across the market create new business possibilities for the semi-solid dosage contract manufacturing market. The semi-solid dosage forms include creams, gels, and ointments, delivering precise treatment to specific areas, thus making them optimal for dermatology therapy and treating pain and infections. The growing number of cases worldwide for these conditions drives market expansion, thus creating an extensive business prospect for contract manufacturers to fulfill increasing market needs.

Specialized CMOs benefit from the pharmaceutical industry outsourcing of manufacturing services, which helps companies decrease production costs and boost efficiency. Semi-solid formulation development for targeted patient needs creates a new growth opportunity within the rising personal medicine trend. The market can expand through CMOs that use production method innovations with improved scalability to serve new emerging trends.

Segment Insights

Type Insights

The topical segment held the largest semi-solid dosage contract manufacturing market share in 2025. CMOs serve as essential service providers for pharmaceutical and biotechnology industries by integrating expertise in developing and manufacturing creams, gels, ointments, and additional topical products. The pharmaceutical industry has begun sending its manufacturing operations to external partners because companies need to control operational spending while also gaining access to specialized capabilities.

The growing market demand for skin care products creates an attractive business alliance between CMOs and cosmetic companies to jointly develop creams, serums, and lotions. A collaborative strategy between pharmaceutical producers and cosmetic manufacturers leads to the growing popularity of the topical segment in the market.

The transdermal segment is anticipated to show considerable growth over the forecast period. By utilizing transdermal drug systems, healthcare professionals gain control of dosage release, resulting in enhanced treatment performance and reduced unwanted side effects. Such advantages have made transdermal products more popular in treating chronic conditions, including pain, hormonal imbalances, and nicotine addiction.

The transdermal segment experiences expansion because users prefer non-invasive drug delivery methods that are easy to use. The market expansion of pharmaceutical firms into sophisticated drug delivery advancements requires specialized CMOs that can manage the manufacturing of these formulations, thus leading to the segment's growth in the semi-solid dosage contract manufacturing domain.

• In January 2024, Starton Therapeutics introduced its innovative STARSILON transdermal technology delivery platform through a public announcement to improve challenging active pharmaceutical ingredients (API) formulations. The technology system strives to enhance drug performance while also extending drug availability and ensuring better patient adherence.

Product Insights

The creams segment contributed the largest semi-solid dosage contract manufacturing market share in 2025. The rising dermatological conditions, including eczema, psoriasis, and acne, and increasing consumer demand for skin care products for aging have substantially boosted cream market requirements. Modifications in bioavailability, skin penetration, and stability have resulted in modern creams that perform more effectively with extended-lasting action.

Market demand for high-quality creams increases continually because consumers look for targeted and effective skincare solutions, thus solidifying their market position. Pharmaceutical and skincare businesses partner with advanced production contract manufacturers to efficiently address rising consumer needs.

Company Size Insights

The large-sized companies segment dominated the global semi-solid dosage contract manufacturing market in 2025. The pharmaceutical market depends on the ability to use contract manufacturing services for semi-solid dosage forms. The high penetration of the segment exists because pharmaceutical organizations choose to concentrate on their fundamental areas while using third-party manufacturers to cut expenses and maximize operations efficiency.

Large companies engage in extensive production orders that need strict regulatory adherence to make sure contract manufacturers fulfill superior industry criteria regarding product quality and safety needs. This method allows them to serve increasing market requirements and efforts to develop new products. Markets seeking semi-solid formulations and their requirement for affordable, scalable production platforms are the main forces behind segment growth.

The medium and small-sized companies segment is projected to show considerable growth in the forecast period. SME pharmaceutical and cosmeceutical companies depend more often on contract manufacturing organizations (CMOs) to access affordable industry technology solutions and advanced manufacturing processes.

These companies do not possess enough capital to build their production buildings they find CMO services appealing. The cosmeceutical industry has started to outsource semi-solid dosage form production, including creams, serums, and lotions, for small-to-medium enterprises to enhance their response to high-quality skincare and personal care product market demand.

End Use Insights

The pharmaceutical companies segment accounted for the largest semi-solid dosage contract manufacturing market share in 2025. The pharmaceutical industry keeps outsourcing its production activities because of the increasing need to work with contract manufacturing organizations. The production services of CMOs constitute a fundamental solution for smaller and medium-sized pharmaceutical companies that want to concentrate on their research and development activities while lowering expenses and enhancing manufacturing effectiveness.

The manufacturing of semi-solid dosage forms through outsourcing enables pharmaceutical companies to gain established, cost-effective production without building extensive in-house facilities while ensuring consistent outputs of creams, gels, and ointments. The demand for market expansion in pharmaceutical production continues to rise due to contract manufacturers' delivery of advanced production technology and experienced workforce capabilities.

The cosmeceutical companies segment is anticipated to show considerable growth in the forecast period. Cosmeceuticals represent cosmetic products that use pharmaceutical-grade elements, which enables their manufacturing through third-party vendors so companies maintain operational focus.

Customers seek a wide range of cosmeceutical solutions, which include skincare, haircare, personal care, and specialized organic and vegan cosmetic categories because they seek comprehensive beauty solutions that match their specific requirements. The growing market segment where wellness and health industries produce a combination of beauty and therapeutic products supports the expansion potential of cosmeceutical contract manufacturing services.

Semi-Solid Dosage Contract Manufacturing Market Companies

• Lonza Group Ltd.
• Lubrizol Life Science
• Cambrex Corporation
• Contract Pharmaceuticals Limited
• Bora Pharmaceutical CDMO
• Ascendia Pharmaceuticals
• Pierre Fabre group
• Piramal Pharma Solutions
• DPT Laboratories, LTD
• MedPharm Ltd
• Catalent, Inc.
• Recipharm AB
• Aenova Group
• Almac Group
• Ajinomoto Bio-Pharma Services

Segments Covered in the Report

By Type

• Topical
• Transdermal
• Oral

By Product

• Creams
• Ointments
• Gels
• Lotions
• Pastes
• Others

By Company Size

• Large Size Companies
• Medium and Small Size Companies
• Others

By End Use

• Pharmaceutical Companies
• Cosmeceutical Companies
• Others

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa